Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
ACRS Aclaris Therapeutics
15.860
+0.640+4.20%
Post Mkt Price
15.8600.0000.00%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Total revenue
1,046.35% 19.02M -16.23% 1.53M -18.23% 1.45M 4.30% 6.76M
Operating revenue
1,241.91% 18.99M -24.16% 1.22M -20.46% 1.22M 0.76% 5.83M
Cost of revenue
648.23% 8.22M -15.44% 1.07M -3.91% 1.16M -8.18% 4.71M
Gross profit
1,827.68% 10.8M -18.00% 460K -48.17% 298K 51.82% 2.05M
Operating expense
47.68% 29.47M 80.53% 24.85M 61.11% 20.41M 29.03% 67.43M
Selling and administrative expenses
-2.78% 5.81M 3.49% 6.08M 26.35% 6.1M 15.05% 23.62M
-General and administrative expense
-2.78% 5.81M 3.49% 6.08M 26.35% 6.1M 15.05% 23.62M
Research and development costs
69.26% 23.66M 137.80% 18.78M 82.52% 14.31M 38.08% 43.81M
Operating profit
3.72% -18.67M -84.72% -24.39M -66.31% -20.11M -28.43% -65.38M
Net non-operating interest income expense
Other net income (expense)
27.01% -1.28M 177.94% 3.86M 107.91% 1.32M -5,909.67% -25.48M
Special income (charges)
-144.44% -2.2M 170.83% 3.4M 107.30% 1.2M -- -24.34M
-Less:Restructuring and merger&acquisition
144.44% 2.2M -170.83% -3.4M -107.30% -1.2M -- 24.34M
-Less:Impairment of capital assets
-- -- -- -- -- -- -- 0
Other non- operating income (expenses)
208.34% 922K 398.06% 462K 152.44% 118K -169.34% -1.14M
Income before tax
5.65% -19.95M -13.06% -20.53M 34.66% -18.79M -77.00% -90.87M
Income tax
0
Net income
5.65% -19.95M -13.06% -20.53M 34.66% -18.79M -78.11% -90.87M
Net income continuous Operations
5.65% -19.95M -13.06% -20.53M 34.66% -18.79M -77.63% -90.87M
Net income discontinuous operations
-- -- -- -- -- -- -- 0
Minority interest income
Net income attributable to the parent company
5.65% -19.95M -13.06% -20.53M 34.66% -18.79M -78.11% -90.87M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
5.65% -19.95M -13.06% -20.53M 34.66% -18.79M -78.11% -90.87M
Basic earnings per share
14.29% -0.3 8.82% -0.31 45.61% -0.31 -33.33% -1.6
Diluted earnings per share
14.29% -0.3 8.82% -0.31 45.61% -0.31 -33.33% -1.6
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
------Unqualified Opinion

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.
CEO: Dr. Neal Walker
Market: NASDAQ
Listing Date: 10/07/2015
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist